Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Allergy ; 68(12): 1546-54, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24266677

ABSTRACT

BACKGROUND: Recent immunological data demonstrated that dendritic cells preferentially recognize advanced glycation end product (AGE)-modified proteins, upregulate expression of the receptor for AGE (RAGE), and consequently bias the immune response toward allergy. METHODS: Peanut extract was characterized by mass spectrometry (MS) to elucidate the specific residues and specific AGE modifications found in raw and roasted peanuts and on rAra h 1 that was artificially glycated by incubation with glucose or xylose. The binding of the RAGE-V1C1 domain to peanut allergens was assessed by PAGE and Western analysis with anti-Ara h 1, 2, and 3 antibodies. IgE binding to rAra h 1 was also assessed using the same methods. RESULTS: AGE modifications were found on Ara h 1 and Ara h 3 in both raw and roasted peanut extract. No AGE modifications were found on Ara h 2. Mass spectrometry and Western blot analysis demonstrated that RAGE binds selectively to Ara h 1 and Ara h 3 derived from peanut extract, whereas the analysis failed to demonstrate Ara h 2 binding to RAGE. rAra h 1 with no AGE modifications did not bind RAGE; however, after AGE modification with xylose, rAra h 1 bound to RAGE. CONCLUSIONS: AGE modifications to Ara h 1 and Ara h 3 can be found in both raw and roasted peanuts. Receptor for AGE was demonstrated to selectively interact with AGE-modified rAra h 1. If sensitization to peanut allergens occurs in dendritic cells via RAGE interactions, these cells are likely interacting with modified Ara h 1 and Ara h 3, but not Ara h 2.


Subject(s)
Allergens/chemistry , Arachis/chemistry , Glycation End Products, Advanced/metabolism , Maillard Reaction , Allergens/immunology , Amino Acid Sequence , Antigens, Plant/chemistry , Antigens, Plant/immunology , Antigens, Plant/metabolism , Arachis/immunology , Glycation End Products, Advanced/chemistry , Glycation End Products, Advanced/immunology , Glycoproteins/immunology , Glycoproteins/metabolism , Glycosylation , Humans , Immunoglobulin E/immunology , Immunoglobulin E/metabolism , Membrane Proteins , Models, Molecular , Plant Proteins/chemistry , Plant Proteins/immunology , Plant Proteins/metabolism , Protein Binding , Protein Conformation , Tandem Mass Spectrometry
2.
Leukemia ; 18(8): 1364-72, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15269783

ABSTRACT

The MLL gene at chromosome band 11q23 is commonly involved in reciprocal translocations detected in acute leukemias. A number of experiments show that the resulting MLL fusion genes directly contribute to leukemogenesis. Among the many known MLL fusion partners, AF4 is relatively common, particularly in acute lymphoblastic leukemia in infants. The AF4 protein interacts with the product of another gene, AF9, which is also fused to MLL in acute leukemias. Based on mapping studies of the AF9-binding domain of AF4, we have developed a peptide, designated PFWT, which disrupts the AF4-AF9 interaction in vitro and in vivo. We provide evidence that this peptide is able to inhibit the proliferation of leukemia cells with t(4;11) chromosomal translocations expressing MLL-AF4 fusion genes. Further, we show that this inhibition is mediated through apoptosis. Importantly, the peptide does not affect the proliferative capacity of hematopoietic progenitor cells. Our findings indicate that the AF4-AF9 protein complex is a promising new target for leukemia therapy and that the PFWT peptide may serve as a lead compound for drug development.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Leukemia/pathology , Nuclear Proteins/metabolism , Oligopeptides/pharmacology , Amino Acid Sequence , Antineoplastic Agents/chemical synthesis , Cell Line, Tumor , Chromosomes, Human, Pair 11 , Chromosomes, Human, Pair 4 , Drug Delivery Systems , Humans , Leukemia/drug therapy , Leukemia/genetics , Myeloid-Lymphoid Leukemia Protein , Nuclear Proteins/drug effects , Oligopeptides/chemical synthesis , Oncogene Proteins, Fusion , Protein Binding/drug effects , Transfection , Translocation, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...